{"entity":{"id":"nct06045767","kind":"trial","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","aka":[],"tldr":"A phase 2 trial in lung cancer, run by Ari Raphael, not yet recruiting.","summary":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer is a phase 2, interventional study registered as NCT06045767 by Ari Raphael, with a registry enrolment figure of 30 participants, started 2024-06 and due to reach its primary completion in 2029-01. Interventions recorded: Pembrolizumab 50 MG Injection [Keytruda]. Conditions listed: Non-small Cell Lung Cancer Metastatic. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1 - correlated to TCR repertoire data, such as clonality/diversity.. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06045767","url":"https://clinicaltrials.gov/study/NCT06045767"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06045767","phase":"2","setting":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","sponsor":"Ari Raphael","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06045767/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}